{
  "trial_id": "NCT04551495",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Female",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age \u2265 18 years",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Histological diagnosis of invasive lobular breast adenocarcinoma that is ER+, and HER2- as per the updated American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) guidelines according to local testing.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Multifocal unilateral or bilateral breast adenocarcinoma tumours are allowed if all tested foci are lobular, ER+ and HER2-.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "ER positive (ER+ is defined as having an IHC of 1% or more and/or an Allred of 3 or more and HER2-).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "HER2 negative (HER2- is defined as having an IHC of 0 or 1+ without ISH OR IHC 2+ and ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells OR ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells [without IHC]).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A primary non metastatic or locally advanced tumour of 15 mm or more, cN0 or cN1 without prior treatment candidate for preoperative treatment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "ECOG Performance Status (PS) 0 or 1.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adequate Bone Marrow Function including: Absolute Neutrophil Count (ANC) \u22651500/\u03bcL or \u22651.5x109/L; Platelets \u2265100000/\u03bcL or \u2265100 x 109/L; Haemoglobin \u2265 9 g/dL.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adequate Renal Function including: Serum creatinine \u2264 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \u2265 60 ml/min as calculated using the method standard for the institution.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adequate Liver Function, including all of the following parameters: Total serum bilirubin \u2264 2.0 x ULN unless the subject has documented Gilbert syndrome; Aspartate and Alanine Aminotransferase (AST and ALT) \u2264 3 x ULN;",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Signed Informed Consent form (ICF) obtained prior to any study related procedure.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Clinical T4 disease including inflammatory breast cancer and/or cN3.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Prior history of invasive cancer in the past 5 years except basal or squamous cell carcinoma of skin that has been definitively treated.",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT04551495",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}